On June 11, 2024 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston (Press release, Nykode Therapeutics, JUN 11, 2024, View Source [SID1234644264]). The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It also provided superior tumor control and resulted in dramatically improved survival rates in a mouse model of colorectal cancer

Chief Scientific Officer, Agnete Fredriksen, commented on the findings, "Our latest data not only emphasize the effectiveness of the APC-targeted approach but also confirm our platform’s potential across modalities to significantly advance the treatment landscape for cancer. The strong data demonstrating Nykode’s potential to improve mRNA vaccines underscore our commitment to leading the way in next-generation immunotherapies."

Nykode presented a poster detailing these findings at the meeting, with further information available on the Nykode website: View Source